Drug Discovery
ByCan AbbVie’s 2025 Launches and Portfolio Expansion Offset Post-Humira Transition and Drive Sustainable Growth Beyond 2026?
Global | January 2026 — AbbVie Inc. accelerated its post-Humira transformation in 2025, advancing a diversified portfolio across…
Can Merck’s 2025 Launches, Label Expansions, and Oncology Leadership Sustain Growth Momentum Into 2026 and Beyond?
Global | January 2026 — Merck & Co., Inc. (MSD outside the U.S. and Canada) reinforced its position…
Can Eli Lilly’s 2025 Brand Launches and Label Expansions Redefine Leadership in Metabolic, Oncology, and Neuroscience Markets Beyond 2026?
Global | January 2026 — Eli Lilly and Company accelerated its transformation in 2025 through a series of…
Can Pfizer’s 2025 Brand Launches Across Vaccines, Oncology, and Specialty Care Reshape Its Growth Trajectory Beyond 2026?
Global | January 2026 — Pfizer Inc. advanced its post-pandemic transformation in 2025 through a series of targeted…
AstraZeneca Reports 2025 Performance with Strong Brand Momentum Across Core Therapeutic Areas
AstraZeneca today announced its full-year 2025 results, reflecting continued growth across oncology, cardiovascular-renal-metabolism (CVRM), respiratory & immunology, and…
GSK Reports Full-Year 2025 Results with Strategic Portfolio Focus
GSK today reported its full-year performance for 2025 and outlined its strategic approach to long-term growth across vaccines,…
